Something else that hasn't been mentioned is the significant cost of running trials. Halving the patients will be a massive expenditure not needeed. While highly unlikely to halve the cost, it could potentially save us a quarter or even a third of the original forecast expense as compared to what it would have cost a week ago. I think our q4 books are going to look pretty good.
Something else that hasn't been mentioned is the significant...
-
- There are more pages in this discussion • 968 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
0.001(0.91%) |
Mkt cap ! $402.5M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.6¢ | 5.5¢ | $393.2K | 7.114M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 391847 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 807151 | 8 |
View Market Depth
| Last trade - 10.57am 25/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |